Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. more
Time Frame | GNFT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.04% | -2.06% | -0.55% |
1-Month Return | -13.27% | -1.92% | 2.72% |
3-Month Return | -12.67% | -10.4% | 7.66% |
6-Month Return | -8.67% | -4.6% | 10.15% |
1-Year Return | -3.32% | 4.06% | 27.53% |
3-Year Return | -32.92% | 1.94% | 32.31% |
5-Year Return | -77.43% | 36.48% | 89.2% |
10-Year Return | -82.9% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 30.84M | 765.00K | 80.07M | 20.20M | 28.57M | [{"date":"2019-12-31","value":38.52,"profit":true},{"date":"2020-12-31","value":0.96,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25.22,"profit":true},{"date":"2023-12-31","value":35.68,"profit":true}] |
Cost of Revenue | - | 202.00K | 161.00K | 248.00K | 341.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":59.24,"profit":true},{"date":"2021-12-31","value":47.21,"profit":true},{"date":"2022-12-31","value":72.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 30.84M | 563.00K | 79.91M | 19.95M | 28.22M | [{"date":"2019-12-31","value":38.59,"profit":true},{"date":"2020-12-31","value":0.7,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":24.96,"profit":true},{"date":"2023-12-31","value":35.32,"profit":true}] |
Gross Margin | 100.00% | 73.59% | 99.80% | 98.77% | 98.81% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":73.59,"profit":true},{"date":"2021-12-31","value":99.8,"profit":true},{"date":"2022-12-31","value":98.77,"profit":true},{"date":"2023-12-31","value":98.81,"profit":true}] |
Operating Expenses | 88.67M | 78.35M | 48.11M | 47.50M | 54.80M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":88.37,"profit":true},{"date":"2021-12-31","value":54.26,"profit":true},{"date":"2022-12-31","value":53.56,"profit":true},{"date":"2023-12-31","value":61.81,"profit":true}] |
Operating Income | (57.83M) | (77.79M) | 76.74M | (27.55M) | (26.58M) | [{"date":"2019-12-31","value":-75.36,"profit":false},{"date":"2020-12-31","value":-101.37,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.9,"profit":false},{"date":"2023-12-31","value":-34.64,"profit":false}] |
Total Non-Operating Income/Expense | (16.39M) | (37.50M) | 30.39M | 6.91M | (3.35M) | [{"date":"2019-12-31","value":-53.93,"profit":false},{"date":"2020-12-31","value":-123.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.73,"profit":true},{"date":"2023-12-31","value":-11.03,"profit":false}] |
Pre-Tax Income | (65.72M) | (101.65M) | 69.47M | (23.84M) | (28.51M) | [{"date":"2019-12-31","value":-94.6,"profit":false},{"date":"2020-12-31","value":-146.31,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-34.31,"profit":false},{"date":"2023-12-31","value":-41.04,"profit":false}] |
Income Taxes | (576.00K) | (428.00K) | 2.21M | (116.00K) | 380.00K | [{"date":"2019-12-31","value":-26,"profit":false},{"date":"2020-12-31","value":-19.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5.24,"profit":false},{"date":"2023-12-31","value":17.16,"profit":true}] |
Income After Taxes | (65.14M) | (101.22M) | 67.26M | (23.72M) | (28.89M) | [{"date":"2019-12-31","value":-96.86,"profit":false},{"date":"2020-12-31","value":-150.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.27,"profit":false},{"date":"2023-12-31","value":-42.96,"profit":false}] |
Income From Continuous Operations | (65.14M) | (101.22M) | 67.26M | (23.72M) | (28.89M) | [{"date":"2019-12-31","value":-96.86,"profit":false},{"date":"2020-12-31","value":-150.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.27,"profit":false},{"date":"2023-12-31","value":-42.96,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (65.14M) | (101.22M) | 67.26M | (23.72M) | (28.89M) | [{"date":"2019-12-31","value":-96.86,"profit":false},{"date":"2020-12-31","value":-150.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.27,"profit":false},{"date":"2023-12-31","value":-42.96,"profit":false}] |
EPS (Diluted) | - | (3.25) | - | 0.11 | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2881.99,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
GNFT | |
---|---|
Cash Ratio | 1.69 |
Current Ratio | 3.74 |
Quick Ratio | 3.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GNFT | |
---|---|
ROA (LTM) | 6.51% |
ROE (LTM) | 25.91% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GNFT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.50 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.50 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GNFT | |
---|---|
Trailing PE | 9.38 |
Forward PE | 7.27 |
P/S (TTM) | 2.27 |
P/B | 1.85 |
Price/FCF | NM |
EV/R | 2.43 |
EV/Ebitda | 6.44 |
Genfit (GNFT) share price today is $3.79
Yes, Indians can buy shares of Genfit (GNFT) on Vested. To buy Genfit from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GNFT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Genfit (GNFT) via the Vested app. You can start investing in Genfit (GNFT) with a minimum investment of $1.
You can invest in shares of Genfit (GNFT) via Vested in three simple steps:
The 52-week high price of Genfit (GNFT) is $6.42. The 52-week low price of Genfit (GNFT) is $3.31.
The price-to-earnings (P/E) ratio of Genfit (GNFT) is 9.3846
The price-to-book (P/B) ratio of Genfit (GNFT) is 1.85
The dividend yield of Genfit (GNFT) is 0.00%
The market capitalization of Genfit (GNFT) is $182.66M
The stock symbol (or ticker) of Genfit is GNFT